CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00482911
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:38.215840+00:00
Published At: 2012-11-14T00:00:00+00:00
Record Updated At: 2017-03-27
Results Posted At: 2012-11-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Intraocular Melanoma", "Malignant Conjunctival Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-03-27"
protocolSection.identificationModule.nctId: "NCT00482911"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid\u2122), Oral Sunitinib (Sutent\u2122) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2012-11-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.